John McCamant
Medical Technology Stock Letter
John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.
Recent Quotes
"CBMG is putting together a huge portfolio of assets in cancer."
—
The Life Sciences Report Interview with John McCamant
(9/16/15)
more >
"CBMG's world-class pipeline is still below Wall Street's radar."
—
John McCamant, Medical Technology Stock Letter
(6/11/15)
more >
"CBMG is a recently transformed company."
—
The Life Sciences Report with John McCamant
(5/12/15)
more >
"We continue to believe that OGXI is undervalued."
—
John McCamant, Medical Technology Stock Letter
(12/21/12)
more >
"The potential of CYCC's phase 3 trial with AML gives the Street more confidence."
—
The Life Sciences Report Interview with John McCamant
(10/25/12)
more >
"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger."
—
The Life Sciences Report Interview with John McCamant
(10/4/12)
more >
"We continue to believe that OGXI is undervalued."
—
John McCamant, Medical Technology Stock Letter
(7/20/12)
more >
"Data from OGXI's phase 2 trial for OGX-427 is encouraging."
—
John McCamant, Medical Technology Stock Letter
(6/8/12)
more >
